Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
May 2024
Historique:
medline: 1 6 2024
pubmed: 1 6 2024
entrez: 1 6 2024
Statut: ppublish

Résumé

Conflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low- and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI. We designed an online 27-question-based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings. ONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI. These findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.

Identifiants

pubmed: 38822759
doi: 10.1200/GO.24.00167
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400167

Auteurs

Khalid El Bairi (K)

Faculty of Medical Sciences, University Mohammed VI Polytechnic, Ben Guerir, Morocco.

Salma Najem (S)

Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.

Arman Reza Chowdhury (AR)

Evercare Cancer Centre, Evercare Hospital, Dhaka, Bangladesh.

Abeid Omar (A)

Department of Oncology and Nuclear Medicine, Research and Referral Hospital Kenyatta Teaching University, Nairobi, Kenya.

Omar Abdihamid (O)

Garissa Cancer Center, Garissa County Hospital, Garissa, Kenya.

Laure-Anne Teuwen (LA)

Department of Oncology, Antwerp University Hospital, Edegem, Belgium.

Nada Benhima (N)

Medical Oncology Department, Mohammed VI University Hospital, Marrakech, Morocco.

Ainhoa Madariaga (A)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Safa Elkefi (S)

School of Nursing, Columbia Medical School, Columbia University, New York, NY.

Fernando Cristobal Diaz (FC)

Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC.

Sadaqat Hussain (S)

Oncology Department, University Hospital of Leicester, Licester, United Kingdom.

Kristina Jenei (K)

Health Policy Department, London School of Economics and Political Science, London, United Kingdom.

Nazik Hammad (N)

Division of Hematology-Oncology, St Michael's Hospital, University of Toronto, Toronto, Canada.

Miriam Mutebi (M)

Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya.

Fidel Rubagumya (F)

Rwanda Military Hospital, Kigali, Rwanda.

Dario Trapani (D)

Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
University of Milan, Milan, Italy.

Nadia El Kadmiri (N)

Molecular Engineering, Biotechnology, and Innovation Team, Geo-Bio-Environment Engineering and Innovation Laboratory, Polydisciplinary Faculty of Taroudant, Ibn Zohr University, Taroudannt, Morocco.

Nasser Laouali (N)

Faculty of Medical Sciences, University Mohammed VI Polytechnic, Ben Guerir, Morocco.

Maryam Fourtassi (M)

Laboratory of Life and Health Sciences, Faculty of Medicine and Pharmacy of Tangier, Abdelmalek Essaadi University, Tetuan, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH